About half of the adult patients with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve a molecular complete remission or who subsequently relapse cannot be cured with the current chemotherapy or targeted agents. In recent years, however, we have witnessed the emergence of different immune-based therapies in this setting. This includes monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibodydrug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs).